文献速递肝病

美国慢性乙型肝炎病毒感染管理治疗算法:2021年更新

Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-07-27

该更新版算法由北美肝病专家小组制定,旨在指导慢性乙型肝炎(CHB)的管理。文章指出丙酚替诺福韦(TAF)因安全性优于富马酸替诺福韦二吡呋酯(TDF)而成为初始抗病毒选择,乙肝表面抗原定量检测的应用日益广泛,且新证据挑战了免疫耐受期疾病不进展的传统观念,同时美国CHB患者平均年龄增加使合并症管理更为重要。推荐基于科学文献证据、临床经验和专家共识。

要点

  • 丙酚替诺福韦(TAF)安全性优于富马酸替诺福韦二吡呋酯(TDF),可作为初始抗病毒选择及长期治疗替代方案。
  • 乙肝表面抗原定量检测在临床实践中日益普及,对监测治疗应答具有意义。
  • 新证据挑战免疫耐受期疾病不进展的观念,且美国CHB患者平均年龄增加,合并症管理日益重要。

核心结论

  • 该更新算法旨在为慢性乙型肝炎(CHB)的管理提供指导,直至新的抗病毒策略问世。

研究设计与样本

  • 2004年由北美肝病专家小组制定CHB管理算法,其后于2006、2008和2015年更新,本次为2021年更新。

主要发现

  • 丙酚替诺福韦(TAF)安全性优于富马酸替诺福韦二吡呋酯(TDF),已作为初始抗病毒选择及长期治疗替代方案引入。
  • 乙肝表面抗原定量检测在临床实践中日益普及,对监测治疗应答具有意义。
  • 新证据挑战了免疫耐受期感染疾病不进展的观念。
  • 美国CHB患者平均年龄增加,合并症(包括代谢性肝病)及随年龄增长的生物制剂使用将日益影响疾病管理。

关键数值与推荐

  • 推荐尽可能基于科学文献证据,并辅以临床经验和共识专家意见。
  • 文中描述了持续争议点和研究需求领域。

临床怎么用

  • 临床医生可参考该算法管理CHB,考虑将TAF作为初始或长期治疗选择,并关注乙肝表面抗原定量监测及合并症管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic hepatitis B (CHB) infection remains the most frequent etiology of hepatocellular carcinoma globally as well as a major cause of cirrhosis. Despite vaccination, substantial numbers of persons have already been infected with hepatitis B virus and remain at risk of progressive liver disease. METHODS: In 2004, a CHB management algorithm was developed by a panel of North American hepatologists, which was subsequently updated in 2006, 2008, and 2015. Since the most recent version, several developments have altered the management of CHB. Tenofovir alafenamide, with a more favorable safety profile than tenofovir disoproxil fumarate, has been introduced as an initial antiviral choice as well as an alternative for long-term therapy. Quantitation of hepatitis B surface antigen is becoming more widely available in clinical practice, with implications for monitoring response to treatment. Additionally, there has been a shift in how the natural history of CHB is perceived, as newer evidence has challenged the concept that during the immunotolerant phase of infection disease progression is not a concern. Finally, recent analyses indicate that in the United States, the average age of patients with CHB has increased, implying that the presence of comorbidities, including metabolic liver disease, increasing use of biologics associated with aging will increasingly affect disease management. RESULTS: This updated algorithm is intended to serve as a guide to manage CHB while new antiviral strategies are developed. CONCLUSIONS: Recommendations have been based on evidence from the scientific literature, when possible, as well as clinical experience and consensus expert opinion. Points of continued debate and areas of research need are also described.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Martin P, Nguyen MH, Dieterich DT, et al. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol. 2021. PMID: 34329775. doi:10.1016/j.cgh.2021.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。